X4 Pharmaceuticals (XFOR) Financials: Revenue & Earnings
XFOR$3.29+0.04 +1.08%
$325.70M
Market Cap
-2.67
P/E
2.78
Forward P/E
—
Score
X4 Pharmaceuticals (XFOR) Financials: Revenue & Earnings
XFOR price $3.29 +0.04 +1.08%
- Ticker
- XFOR
- Price
- $3.29
- Change
- +0.04 +1.08%
- Market cap ?
- $325.70M
- P/E ?
- -2.67
- Forward P/E ?
- 2.78
- Dividend yield ?
- 0.00%
- Beta ?
- 0.35
- Sector
- Healthcare
- Industry
- Biotechnology
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 3000000 | 0 | 0 | 0 | 2557000 | 35113000 |
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical…
Fair value
XFOR fair value $24.07. Price $3.29. Price is 86% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 3.35M. Growth 0.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 99.15M. Net debt -139.76M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-04 | — | -0.18 | — | 2.30M |
| 2026-08-07 | -0.13 | -0.18 | 8.81M | 2.42M |
| 2026-05-06 | -0.16 | -0.20 | 2.71M | 3.20M |
| 2026-03-17 | -0.22 | -0.36 | 2.57M | 1.73M |
| 2025-11-05 | -0.69 | -0.79 | 1.76M | 1.90M |
| 2025-08-08 | -3.47 | -4.53 | 1.97M | 1.62M |
| 2025-05-01 | 0.04 | -4.13 | 28.81M | 11.58M |
| 2025-03-25 | -6.01 | -5.11 | 1.43M | 1.06M |
| 2024-11-13 | -5.41 | -5.11 | 560.00K | 1.69M |
| 2024-08-08 | -2.10 | -0.21 | 563.00K | 15.27M |
| 2024-05-07 | -7.81 | -0.17 | — | — |
| 2024-03-21 | -3.00 | -0.15 | — | — |
| 2023-11-09 | -0.30 | -0.15 | — | — |
| 2023-08-10 | -9.91 | -0.17 | — | — |
| 2023-05-04 | -4.80 | -0.22 | — | — |
| 2023-03-21 | -8.71 | -0.27 | — | — |
| 2022-11-03 | -7.81 | -0.30 | — | — |
| 2022-08-04 | -17.96 | -0.64 | — | — |
| 2022-05-12 | -0.72 | -0.61 | — | 128.57K |
| 2022-03-17 | -37.14 | -0.68 | — | — |
| 2021-11-04 | -22.82 | -21.62 | — | — |
| 2021-08-03 | -22.22 | -21.92 | — | — |
| 2021-05-06 | -39.04 | -25.23 | — | — |
| 2021-03-04 | -27.33 | -26.13 | 0 | — |
| 2020-11-05 | -26.13 | -22.22 | — | — |
| 2020-07-30 | -22.82 | -21.02 | — | 2.84M |
| 2020-05-07 | -16.82 | -24.92 | 3.00M | 4.29M |
| 2020-03-12 | -19.82 | -22.82 | — | 4.40M |
| 2019-11-07 | -28.53 | -30.33 | — | — |
| 2019-08-06 | -30.63 | -23.72 | — | — |
| 2019-05-15 | -200.30 | — | — | — |
| 2019-03-11 | -3.92 | -4.44 | 3.50M | — |
| 2018-11-09 | -4.56 | -3.88 | — | — |
| 2018-08-13 | -5.10 | -4.90 | — | — |
| 2018-05-10 | -4.44 | -6.24 | — | — |
| 2018-03-09 | -10.08 | -17.80 | — | — |
| 2017-11-17 | -24,411.00 | — | — | — |
| 2017-03-31 | -5.80 | — | — | — |
| 2016-12-31 | -5.73 | — | — | — |
| 2016-03-30 | -8.81 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-16 | Craig Adam R | Buy | 4.60K | $2.58 | 11.88K |
| 2026-10-01 | KIRSKE DAVID | Sell | 11.77K | $2.86 | 33.66K |
| 2026-08-12 | Volpone John | Sell | 24.58K | $4.44 | 109.23K |
| 2026-08-12 | Craig Adam R | Sell | 47.44K | $4.44 | 210.83K |
| 2026-07-01 | Gold Kelly | Buy | 110.00K | $4.08 | 449.35K |
| 2026-07-01 | Gold Kelly | Other | 0 | — | — |
| 2026-06-30 | KIRSKE DAVID | Sell | 8.54K | $4.26 | 36.43K |
| 2026-05-12 | KIRSKE DAVID | Sell | 16.96K | $4.29 | 72.82K |
| 2026-01-01 | Bridger Gary | Buy | 110.00K | $4.00 | 440.00K |
| 2026-01-01 | de Craecker Francoise | Buy | 110.00K | $4.00 | 440.00K |
| 2026-01-01 | WYZGA MICHAEL S | Buy | 110.00K | $4.00 | 440.00K |
| 2026-01-01 | Stewart Murray | Buy | 110.00K | $4.00 | 440.00K |
| 2025-10-29 | Craig Adam R | Buy | 2.33M | $1.42 | 3.31M |
| 2025-10-29 | Volpone John | Buy | 2.33M | $1.42 | 3.31M |
| 2025-10-29 | KIRSKE DAVID | Buy | 1.55M | $1.42 | 2.20M |
| 2025-10-23 | Craig Adam R | Buy | 86.21K | $2.90 | 250.00K |
| 2025-08-14 | Volpone John | Buy | 529.20K | $3.14 | 1.66M |
| 2025-08-14 | Volpone John | Buy | 289.88K | — | — |
| 2025-08-14 | Craig Adam R | Buy | 529.20K | $3.14 | 1.66M |
| 2025-08-14 | Craig Adam R | Buy | 289.88K | — | — |
| 2025-08-14 | KIRSKE DAVID | Buy | 352.80K | $3.14 | 1.11M |
| 2025-08-14 | KIRSKE DAVID | Buy | 193.25K | — | — |
| 2025-08-12 | Volpone John | Buy | 1.61M | $1.42 | 2.29M |
| 2025-08-12 | Craig Adam R | Other | 0 | — | — |
| 2025-08-12 | KIRSKE DAVID | Other | 0 | — | — |
| 2025-08-12 | Craig Adam R | Buy | 1.61M | $1.42 | 2.29M |
| 2025-08-12 | KIRSKE DAVID | Buy | 1.07M | $1.42 | 1.52M |
| 2025-08-12 | Volpone John | Other | 0 | — | — |
| 2025-06-09 | Stewart Murray | Buy | 1.50K | — | — |
| 2025-06-09 | de Craecker Francoise | Buy | 1.50K | — | — |
| 2025-06-09 | Bridger Gary | Buy | 1.50K | — | — |
| 2025-06-09 | Woods Keith | Buy | 1.50K | — | — |
| 2025-06-09 | MCGIRR DAVID W J | Buy | 1.50K | — | — |
| 2025-06-09 | WYZGA MICHAEL S | Buy | 1.50K | — | — |
| 2025-05-20 | Thoren Natasha Fay | Buy | 3.33K | — | — |
| 2025-05-20 | Thoren Natasha Fay | Other | 0 | — | — |
| 2025-05-20 | Thoren Natasha Fay | Other | 8.17K | $32.70 | 267.03K |
| 2025-05-16 | Baldry Mark | Buy | 1.03K | $2.48 | 2.56K |
| 2025-05-16 | Baldry Mark | Buy | 1.03K | $2.48 | 2.56K |
| 2025-02-12 | Arbet-Engels Christophe | Buy | 850.00K | — | — |
| 2025-02-12 | Mostafa Adam S. | Buy | 850.00K | — | — |
| 2025-02-12 | Ragan Paula | Buy | 2.25M | — | — |
| 2025-02-12 | Baldry Mark | Buy | 600.00K | — | — |
| 2025-02-12 | DiBiase Mary | Buy | 650.00K | — | — |
| 2025-01-24 | Ragan Paula | Sell | 76.47K | $0.45 | 34.72K |
| 2025-01-24 | Mostafa Adam S. | Sell | 74.77K | $0.45 | 33.95K |
| 2025-01-24 | Baldry Mark | Sell | 29.16K | $0.45 | 13.24K |
| 2025-01-24 | DiBiase Mary | Sell | 22.26K | $0.45 | 10.09K |
| 2025-01-24 | Arbet-Engels Christophe | Sell | 11.62K | $0.45 | 5.28K |
| 2025-01-23 | Ragan Paula | Buy | 169.94K | — | — |
| 2025-01-23 | Mostafa Adam S. | Buy | 74.77K | — | — |
| 2025-01-23 | Baldry Mark | Buy | 74.77K | — | — |
| 2025-01-23 | DiBiase Mary | Buy | 61.18K | — | — |
| 2025-01-23 | Arbet-Engels Christophe | Buy | 25.83K | — | — |
| 2024-11-15 | Baldry Mark | Buy | 13.40K | $0.34 | 4.60K |
| 2024-11-15 | Ragan Paula | Sell | 31.90K | $0.39 | 12.58K |
| 2024-10-15 | Ragan Paula | Sell | 31.90K | $0.56 | 17.93K |
| 2024-10-07 | Mostafa Adam S. | Sell | 230.65K | $0.55 | 126.90K |
| 2024-10-07 | Baldry Mark | Sell | 11.13K | $0.58 | 6.51K |
| 2024-10-07 | Ragan Paula | Sell | 239.44K | $0.55 | 131.52K |
| 2024-10-07 | DiBiase Mary | Sell | 67.69K | $0.57 | 38.33K |
| 2024-10-07 | Taveras Arthur | Sell | 76.92K | $0.56 | 43.31K |
| 2024-10-04 | Mostafa Adam S. | Buy | 230.65K | — | — |
| 2024-10-04 | Baldry Mark | Buy | 34.95K | — | — |
| 2024-10-04 | Ragan Paula | Buy | 532.08K | — | — |
| 2024-10-04 | DiBiase Mary | Buy | 230.65K | — | — |
| 2024-10-04 | Taveras Arthur | Buy | 230.65K | — | — |
| 2024-09-09 | DiBiase Mary | Sell | 2.64K | $0.66 | 1.74K |
| 2024-06-10 | de Craecker Francoise | Buy | 45.00K | — | — |
| 2024-06-10 | Aliski William | Buy | 45.00K | — | — |
| 2024-06-10 | MCGIRR DAVID W J | Buy | 45.00K | — | — |
| 2024-06-10 | Stewart Murray | Buy | 45.00K | — | — |
| 2024-06-10 | Bridger Gary | Buy | 45.00K | — | — |
| 2024-06-10 | Woods Keith | Buy | 45.00K | — | — |
| 2024-06-10 | Lawton Alison Frances | Buy | 45.00K | — | — |
| 2024-06-10 | WYZGA MICHAEL S | Buy | 45.00K | — | — |
| 2024-05-17 | Baldry Mark | Buy | 21.65K | $0.68 | 14.65K |
| 2024-03-11 | Taveras Arthur | Sell | 14.23K | $0.88 | 12.55K |
| 2024-03-11 | Ragan Paula | Sell | 49.68K | $0.88 | 43.86K |
| 2024-03-11 | Mostafa Adam S. | Sell | 52.50K | $0.88 | 46.35K |
| 2024-03-11 | DiBiase Mary | Sell | 15.41K | $0.88 | 13.59K |
| 2024-02-13 | Arbet-Engels Christophe | Buy | 180.82K | $0.92 | 166.53K |
| 2024-02-13 | Arbet-Engels Christophe | Buy | 475.83K | $0.92 | 438.24K |
| 2024-02-13 | Mostafa Adam S. | Buy | 523.41K | $0.92 | 482.06K |
| 2024-02-13 | DiBiase Mary | Buy | 428.25K | $0.92 | 394.42K |
| 2024-02-13 | Ragan Paula | Buy | 1.19M | $0.92 | 1.10M |
| 2024-02-13 | Baldry Mark | Buy | 523.41K | $0.92 | 482.06K |
| 2024-02-13 | Taveras Arthur | Buy | 428.25K | $0.92 | 394.42K |
| 2024-02-12 | DiBiase Mary | Sell | 3.68K | $1.01 | 3.71K |
| 2024-02-12 | Taveras Arthur | Sell | 787 | $1.01 | 793 |
| 2024-02-12 | Ragan Paula | Sell | 21.70K | $1.01 | 21.89K |
| 2024-02-12 | Mostafa Adam S. | Sell | 27.72K | $1.01 | 27.97K |
| 2023-11-03 | Ragan Paula | Sell | 39.91K | $0.90 | 35.92K |
| 2023-11-01 | Ragan Paula | Sell | 199.53K | $0.73 | 145.66K |
| 2023-11-01 | Mostafa Adam S. | Sell | 230.65K | $0.73 | 168.37K |
| 2023-11-01 | DiBiase Mary | Sell | 67.69K | $0.73 | 49.42K |
| 2023-11-01 | Baldry Mark | Sell | 10.26K | $0.73 | 7.49K |
| 2023-11-01 | Taveras Arthur | Sell | 67.69K | $0.73 | 49.42K |
| 2023-10-31 | Mostafa Adam S. | Buy | 230.65K | — | — |
| 2023-10-31 | Baldry Mark | Buy | 34.95K | — | — |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 91, holders +10 vs prior quarter. Ownership 76.13%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| MORGAN STANLEY | 9.46M | -5.71K | -0.06% | 44.18M |
| FMR LLC | 8.32M | 218.26K | +2.69% | 38.86M |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 7.97M | 0 | 0.00% | 37.21M |
| PERCEPTIVE ADVISORS LLC | 7.93M | 1.20M | +17.75% | 37.05M |
| SATURN V CAPITAL MANAGEMENT LP | 6.97M | 516.70K | +8.00% | 32.57M |
| EMPERY ASSET MANAGEMENT, LP | 6.93M | -2.01M | -22.51% | 32.37M |
| DEEP TRACK CAPITAL, LP | 5.88M | -460.78K | -7.27% | 27.45M |
| BLACKROCK, INC. | 5.55M | 4.34M | +358.40% | 25.94M |
| KALEHUA CAPITAL MANAGEMENT LLC | 3.72M | 0 | 0.00% | 17.39M |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.72M | 218.25K | +6.24% | 17.35M |
| ROSALIND ADVISORS, INC. | 3.21M | 0 | 0.00% | 15.01M |
| BRAIDWELL LP | 2.92M | -350.20K | -10.70% | 13.65M |
| BLACKSTONE INC. | 2.68M | 0 | 0.00% | 12.52M |
| TRAILS EDGE CAPITAL PARTNERS, LP | 2.57M | 0 | 0.00% | 12.01M |
| NANTAHALA CAPITAL MANAGEMENT, LLC | 2.45M | 0 | 0.00% | 11.44M |
| BVF INC/IL | 2.23M | 0 | 0.00% | 10.43M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.10M | 1.16M | +123.26% | 9.80M |
| VENROCK ADVISER, LLC | 1.93M | 1.60M | +485.21% | 9.03M |
| SAMSARA BIOCAPITAL, LLC | 1.40M | -436.98K | -23.85% | 6.52M |
| STATE STREET CORP | 1.30M | 892.48K | +221.17% | 6.05M |
| WOODLINE PARTNERS LP | 1.00M | 0 | 0.00% | 4.68M |
| GOLDMAN SACHS GROUP INC | 916.54K | 34.40K | +3.90% | 4.28M |
| NORTHERN TRUST CORP | 652.85K | 474.61K | +266.29% | 3.05M |
| VANGUARD FIDUCIARY TRUST CO | 572.04K | 91.31K | +18.99% | 2.67M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 542.13K | 542.13K | New | 2.53M |
Earnings and financials
X4 Pharmaceuticals, Inc. (XFOR) trades at $3.29, with a market cap of $325.70M and a trailing P/E of -2.67. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 3000000 | 0 | 0 | 0 | 2557000 | 35113000 |
Insights · Dividends · Forecast · Financials · Learn